Silo Pharma Inc. has now begun working on a new ketamine drug designed to treat fibromyalgia. Silo Pharma will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics, an SC Launch Inc. Portfolio Company, Z-Pod technology.
The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by memory issues, sleep problems and fatigue. Read more.
|